Trial Search Results

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Stanford Investigator(s):


  • Drug: AZD4877


Phase 2


Inclusion Criteria:

   - Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra).

   - Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by
   curative surgery and/or curative radiotherapy

   - Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable
   and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting.

   - Ambulatory and capable of all selfcare more than 50% of waking hours

Exclusion Criteria:

   - Prior treatment with investigational or standard anti-cancer agents, including
   radiotherapy, within 4 weeks prior to first dose of study medication; 6 weeks if prior
   systemic mitomycin, nitrosourea, or suramin.

   - Inadequate bone marrow reserve

   - Inadequate liver function in the presence of liver metastases

   - Impaired renal function

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting